Results 141 to 150 of about 24,654 (177)
Some of the next articles are maybe not open access.
Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia
International Journal of Hematology, 2016Dasatinib, a second-generation tyrosine kinase inhibitor, is a highly effective treatment for Bcr-Abl-positive leukemia. However, the mechanism by which dasatinib induces cell death is unclear, particularly in vivo. Autophagy is a lysosomal degradation mechanism essential for cell survival and differentiation.
Makiko, Morita +8 more
openaire +2 more sources
Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells
Genes, Chromosomes and Cancer, 2006AbstractBACH2 is a B‐cell‐specific transcription repressor and is also know as a tumor suppressor in B cell malignancy. Expression of BACH2 is induced in BCR‐ABL positive lymphoid cell lines including BV173 by imatinib, a molecular targeting agent for the treatment of chronic myeloid leukemia (CML).
Atsushi, Ono +9 more
openaire +2 more sources
Function of STAT5 Isoforms in Bcr-Abl Positive Cells
Blood, 2011Abstract Abstract 1313 Chronic myeloid leukemia (CML) is caused by expression of the BCR-ABL oncogene product which exerts constitutive tyrosine kinase activity. Specific inhibition of the BCR-ABL tyrosine kinase activity by small tyrosine kinase inhibitors (TKIs) is now well established as initial therapy for newly ...
Michael Schaller-Schoenitz +4 more
openaire +1 more source
Jumping translocation of 1q in a BCR/ABL-positive acute lymphoblastic leukemia
Cancer Genetics and Cytogenetics, 2005Jumping translocations (JT) are rare chromosomal abnormalities in which an identical copy of a chromosomal region (donor) is translocated to a different chromosome (acceptor). Chromosome 1 is often involved as donor chromosome. JTs of the long arm of chromosome 1 (1q) or parts of it are associated with a poor outcome.
Antje-Friederike, Pelz +2 more
openaire +2 more sources
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias
Investigational New Drugs, 2012Effective inhibition of BCR-ABL tyrosine kinase activity with Imatinib represents a breakthrough in the treatment of patients with chronic myeloid leukemia (CML). However, more than 30 % of patients with CML in chronic phase do not respond adequately to Imatinib and the drug seems not to affect the quiescent pool of BCR-ABL positive leukemic stem and ...
Ziegler, P +14 more
openaire +2 more sources
The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells
Biochemical Pharmacology, 2008Chronic myelogenous leukemia (CML) is characterized by the presence of Bcr-Abl oncoprotein. Gleevec has been designed to treat many CML patients by specifically targeting Bcr-Abl, but resistance to it is already apparent in many cases. In CML cells, Bcr-Abl activates several signaling pathways, including the Ras-dependent pathway, in which growth ...
Yun-Bin, Ye +8 more
openaire +2 more sources
ABL-BCR Expression in BCR-ABL-Positive Human Leukemia Cell Lines
Leukemia Research, 1999Expression of normal ABL and BCR and of reciprocal fusion genes BCR-ABL and ABL-BCR was examined in a panel of 53 BCR-ABL-positive cell lines by RT-PCR to determine the influence of the various transcripts on leukemogenesis. Seventeen out of 18 lymphoid cell lines expressed ABL1a and/or ABL1b, whereas only 16 out of 35 myeloid cell lines expressed one ...
Hans G Drexler +2 more
exaly +3 more sources
Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells
Experimental Hematology, 2009No description ...
Ashley, Hamilton +4 more
openaire +3 more sources
Tyrosine kinase inhibitors in BCR/ABL positive ALL.
Journal of Clinical Oncology, 20116536 Background: The treatment of acute lymphocytic leukemia (ALL) represents a success for chemotherapy treatments developed in the early 70’s.
openaire +1 more source
Blood, 2005
Abstract AMN107 is a new, highly potent and selective BCR-ABL inhibitor currently in clinical development for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia ALL (Ph+ALL).
Andreas Hochhaus +14 more
openaire +1 more source
Abstract AMN107 is a new, highly potent and selective BCR-ABL inhibitor currently in clinical development for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia ALL (Ph+ALL).
Andreas Hochhaus +14 more
openaire +1 more source

